Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.32 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.32 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 5/20 | 0.31 |
| ▸ | BRAF | P15056 | 5/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.30 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.30 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729802 | 0.84 | PIK3CA (0.35) | MAPK14MEN1KMT2APIK3CA | |
| SCHEMBL22729562 | 0.78 | PIK3CA (0.34) | MAPK14MEN1KMT2APIK3CARAF1 | |
| SCHEMBL22729654 | 0.71 | TDP1 (0.52) | RAF1BRAF | |
| SCHEMBL22729628 | 0.68 | BRD4 (0.38) | KMT2A | |
| Hydrochloric Acid SCHEMBL22729563 | 0.68 | KDM4E (0.36) | MEN1KMT2A | |
| SCHEMBL22755188 | 0.67 | PIK3CA (0.34) | KCNJ6KCNJ5KCNJ3MAPK14KMT2A | |
| SCHEMBL22729591 | 0.67 | BRD4 (0.47) | MEN1KMT2AHTR3A | |
| SCHEMBL22729793 | 0.66 | ALDH1A1 (0.55) | MEN1KMT2A | |
| SCHEMBL22729460 | 0.63 | BRAF (0.39) | MAPK14RAF1BRAFMAPK13MAPK12 | |
| SCHEMBL19533288 | 0.60 | AURKA (0.33) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | RET 4346/4885KCNJ6 2089/4885KCNJ5 1319/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | RET 4334/4885KCNJ6 2266/4885KCNJ5 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.